The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis

Thomas S. Griffith, Troy J. Kemp

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences